权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Gene Editing and Epigenomics Core

基因编辑和表观基因组学核心

基本信息

批准号：
10438741
负责人：
Stephen Carl Ekker
金额：
$ 19.95万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10438741
关键词：
Attention Bacterial Artificial Chromosomes Biological Assay Biological Models CRISPR/Cas technology ChIP-seq Chromatin Clinic Complex Consultations Coupled Custom DNA DNA Methylation DNA Modification Process DNA Structure Development Digestive System Disorders Discipline Environmental Risk Factor Epigenetic Process Essential Genes Funding Future Gastroenterology Gene Expression Genes Genetic Genetic Models Genetic study Genome Guide RNA Hour Human Resources Immunoprecipitation Infrastructure Internet Journals Laboratories Manuscripts Methods Modification Molecular Names Newsletter Nucleosomes Persons Plasmids Positioning Attribute Price Publications Publishing RNA RNA Editing Reagent Research Research Personnel Resources Services Signal Pathway Signal Transduction Surveys Technology Training Validation animal model development base base editor bisulfite sequencing carboxylate chromatin immunoprecipitation chromosome conformation capture cost design and construction education resources epigenome epigenomics epitranscriptomics genome editing individualized medicine innovation laboratory development member next generation sequencing nuclease programs response symposium tool transcription activator-like effector nucleases transcription factor vector webinar

项目摘要

PROJECT SUMMARY: GENE EDITING AND EPIGENOMICS CORE The C-SiG Gene Editing and Epigenomics Core provides current, emerging, and future gene editing and epigenomic technologies and expertise to center members. The organization and infrastructure of the core provides essential gene editing and epigenomics expertise and dedicated personnel to advise, interact with, provide reagents, and directly support C-SiG members in pursuit of the Specific Aims described below. The core will continue to be led by the Core Director, Dr. Stephen Ekker, who is a well-established molecular geneticist and gene editor and the Associate Core Director, Dr. Tamas Ordog, who is the founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine (CIM). The CIM Epigenomics Program develops, implements, and validates epigenomic technology and offering these methods to investigators. This resource will be leveraged to provide access to a broader segment of the C-SiG membership to state-of-the-art epigenomic methods at a discounted price, through a C-SiG supported technologist (50% FTE). The rapidly evolving disciplines of gene editing and epigenomics provide powerful tools to investigate the complex coordination of gene expression, which is modulated via a web of mechanistic relationships involving signaling pathways, transcription factors, and chromatin packaging. Epigenomics analysis when paired with genetic studies facilitated by gene editing technologies, greatly enhances identification of contributing molecular signaling pathways and environmental factors. Thus, provision of integrated access to gene editing and epigenomics expertise, tools, and assays, provides C-SiG members with a powerful and robust set of technologies to support digestive disease-related cell signaling research. Accordingly, we have defined and will pursue the following Specific Aims: i) Deliver state-of-the-art gene editing and epigenomics tools and assays that are needed by C-SiG members, including custom plasmids, custom nucleases and access to epigenomics assays including chromatin immunoprecipitation coupled with next generation sequencing (ChIP-seq assays), DNA immunoprecipitation-sequencing-based (DIP-seq); ii) Accelerate research by connecting members to gene editing and epigenomics-related consultation and educational opportunities such as seminars, journal clubs, and conferences; iii) Establish cutting-edge molecular tools and methods for custom genome and RNA editing including new DNA base editors, new RNA editing tools, and for epitranscriptomics (RNA modification assays). The C-SiG Gene Editing and Epigenomics Core services have been used by 53% of Center members and supported 29 publications during the past funding cycle.

项目概述：基因编辑与表观基因组学核心